Literature DB >> 32929604

Effect of Breast Cancer and Adjuvant Therapy on Adipose-Derived Stromal Cells: Implications for the Role of ADSCs in Regenerative Strategies for Breast Reconstruction.

Ritihaas Surya Challapalli1, Roisin M Dwyer1, Niall McInerney2, Michael J Kerin1, Aoife J Lowery3.   

Abstract

Tissue engineering using Adipose Derived Stromal Cells (ADSCs) has emerged as a novel regenerative medicine approach to replace and reconstruct soft tissue damaged or lost as a result of disease process or therapeutic surgical resection. ADSCs are an attractive cell source for soft tissue regeneration due to the fact that they are easily accessible, multipotent, non-immunogenic and pro-angiogenic. ADSC based regenerative strategies have been successfully translated to the clinical setting for the treatment of Crohn's fistulae, musculoskeletal pathologies, wound healing, and cosmetic breast augmentation (fat grafting). ADSCs are particularly attractive as a source for adipose tissue engineering as they exhibit preferential differentiation to adipocytes and support maintenance of mature adipose graft volume. The potential for reconstruction with an autologous tissue sources and a natural appearance and texture is particularly appealing in the setting of breast cancer; up to 40% of patients require mastectomy for locoregional control and current approaches to post-mastectomy breast reconstruction (PMBR) are limited by the potential for complications at the donor and reconstruction sites. Despite their potential, the use of ADSCs in breast cancer patients is controversial due to concerns regarding oncological safety. These concerns relate to the regeneration of tissue at a site where a malignancy has been treated and the impact this may have on stimulating local disease recurrence or dissemination. Pre-clinical data suggest that ADSCs exhibit pro-oncogenic characteristics and are involved in stimulating progression, and growth of tumour cells. However, there have been conflicting reports on the oncologic outcome, in terms of locoregional recurrence, for breast cancer patients in whom ADSC enhanced fat grafting was utilised as an alternative to reconstruction for small volume defects. A further consideration which may impact the successful translation of ADSC based regenerative strategies for post cancer reconstruction is the potential effects of cancer therapy. This review aims to address the effect of malignant cells, adjuvant therapies and patient-specific factors that may influence the success of regenerative strategies using ADSCs for post cancer tissue regeneration.

Entities:  

Keywords:  Adipose-derived stromal cells; Breast cancer; Breast reconstruction; Chemotherapy; Host factors

Mesh:

Year:  2020        PMID: 32929604     DOI: 10.1007/s12015-020-10038-1

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  93 in total

1.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

Review 2.  Adipose-Derived Stromal Vascular Fraction Cells: Update on Clinical Utility and Efficacy.

Authors:  Seongho Han; Hyun Min Sun; Ki-Chul Hwang; Sung-Whan Kim
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2015       Impact factor: 1.807

Review 3.  Fat grafting's past, present, and future: why adipose tissue is emerging as a critical link to the advancement of regenerative medicine.

Authors:  Vivian M Hsu; Carrie A Stransky; Louis P Bucky; Ivona Percec
Journal:  Aesthet Surg J       Date:  2012-09       Impact factor: 4.283

4.  Increasing national mastectomy rates for the treatment of early stage breast cancer.

Authors:  Usama Mahmood; Alexandra L Hanlon; Matthew Koshy; Robert Buras; Saranya Chumsri; Katherine H Tkaczuk; Sally B Cheston; William F Regine; Steven J Feigenberg
Journal:  Ann Surg Oncol       Date:  2012-11-08       Impact factor: 5.344

5.  Factors influencing surgical treatment decisions for breast cancer: a qualitative exploration of surgeon and patient perspectives.

Authors:  E Dicks; R Roome; J Chafe; E Powell; F McCrate; C Simmonds; H Etchegary
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

Review 6.  Brown versus white adipose tissue: a mini-review.

Authors:  Christoph H Saely; Kathrin Geiger; Heinz Drexel
Journal:  Gerontology       Date:  2010-12-07       Impact factor: 5.140

7.  Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.

Authors:  Stephanie M Wong; Rachel A Freedman; Yasuaki Sagara; Fatih Aydogan; William T Barry; Mehra Golshan
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

8.  Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment.

Authors:  Todd M Tuttle; Elizabeth B Habermann; Erin H Grund; Todd J Morris; Beth A Virnig
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

9.  The volumetric analysis of fat graft survival in breast reconstruction.

Authors:  Mihye Choi; Kevin Small; Chaya Levovitz; Christina Lee; Ahmed Fadl; Nolan S Karp
Journal:  Plast Reconstr Surg       Date:  2013-02       Impact factor: 4.730

10.  Adipocyte hypertrophy and lipid dynamics underlie mammary gland remodeling after lactation.

Authors:  Rachel K Zwick; Michael C Rudolph; Brett A Shook; Brandon Holtrup; Eve Roth; Vivian Lei; Alexandra Van Keymeulen; Victoria Seewaldt; Stephanie Kwei; John Wysolmerski; Matthew S Rodeheffer; Valerie Horsley
Journal:  Nat Commun       Date:  2018-09-04       Impact factor: 14.919

View more
  1 in total

1.  ADSCs stimulated by resistin promote breast cancer cell malignancy via CXCL5 in a breast cancer coculture model.

Authors:  Yen-Yun Wang; Amos C Hung; Yi-Chia Wu; Steven Lo; Huan-Da Chen; Yuk-Kwan Chen; Ya-Ching Hsieh; Stephen Chu-Sung Hu; Ming-Feng Hou; Shyng-Shiou F Yuan
Journal:  Sci Rep       Date:  2022-09-14       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.